Edgewood Oncology
Edgewood Oncology is a biotech company in Brookline, United States, founded in 2023. It has raised $20.0M across 1 round, most recently a $20.0M Series A in March 2024.
- Headquarters
- Brookline, Massachusetts
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- edgewoodoncology.com
- Total Funding
- $20.0M
- Last Round
- $20.0M Series AMar 2024
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 1 investor for this company. The full record is or through the API.
About
Edgewood Oncology is a clinical-stage biotechnology company founded to advance BTX-A51, a novel small molecule multi-kinase inhibitor that co-targets CK1α, CDK7, and CDK9 to synergistically activate programmed cell death in cancer cells. The company is focused on hematologic malignancies and genetically-defined solid tumors, with active Phase 2a clinical programs in acute myeloid leukemia and breast cancer. Operating as a virtual biotech to maximize agility and efficiency, Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of Hebrew University of Jerusalem, in 2023.
Summary
It lists 1–10 employees. It has raised $20.0M in total across 1 round, most recently a $20.0M Series A round in Mar 2024. Investors include Alta Partners.
Funding History
Mar 2024
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/edgewood-oncology"><img src="https://indexed.vc/api/badge/company/edgewood-oncology" alt="Edgewood Oncology on Indexed.vc" width="260" height="76" /></a>